INCY Stock Recent News
INCY LATEST HEADLINES
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
CNBC's Joe Kernen reports on the latest news.
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Participants Brian Corey Abrahams - RBC Capital Markets, Research Division Conor Thomas MacKay - BMO Capital Markets Equity Research David Neil Lebowitz - Citigroup Inc., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Marc Alan Frahm - TD Cowen, Research Division Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Salveen Jaswal Richter - Goldman Sachs Gro
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Incyte Corporation INCY reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.